[go: up one dir, main page]

ATE275416T1 - Verfahren zur verminderung von krebssymptomen - Google Patents

Verfahren zur verminderung von krebssymptomen

Info

Publication number
ATE275416T1
ATE275416T1 AT99958892T AT99958892T ATE275416T1 AT E275416 T1 ATE275416 T1 AT E275416T1 AT 99958892 T AT99958892 T AT 99958892T AT 99958892 T AT99958892 T AT 99958892T AT E275416 T1 ATE275416 T1 AT E275416T1
Authority
AT
Austria
Prior art keywords
bmp
cancer symptoms
gdf
reducing cancer
morphogen
Prior art date
Application number
AT99958892T
Other languages
English (en)
Inventor
Kuber T Sampath
Charles M Cohen
David C Rueger
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22704676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE275416(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of ATE275416T1 publication Critical patent/ATE275416T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT99958892T 1998-11-13 1999-11-12 Verfahren zur verminderung von krebssymptomen ATE275416T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19123998A 1998-11-13 1998-11-13
PCT/US1999/026636 WO2000029012A2 (en) 1998-11-13 1999-11-12 Methods of alleviating cancer symptoms

Publications (1)

Publication Number Publication Date
ATE275416T1 true ATE275416T1 (de) 2004-09-15

Family

ID=22704676

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99958892T ATE275416T1 (de) 1998-11-13 1999-11-12 Verfahren zur verminderung von krebssymptomen

Country Status (10)

Country Link
EP (2) EP1131087B2 (de)
JP (2) JP4892131B2 (de)
AT (1) ATE275416T1 (de)
AU (1) AU1616700A (de)
CA (1) CA2349038C (de)
DE (1) DE69920033T3 (de)
DK (1) DK1131087T4 (de)
ES (1) ES2226467T5 (de)
PT (1) PT1131087E (de)
WO (1) WO2000029012A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026713A1 (de) * 2000-05-30 2001-12-06 Walter Sebald Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
ATE516042T1 (de) * 2001-09-18 2011-07-15 Genentech Inc Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren
AU2005230854A1 (en) * 2004-03-31 2005-10-20 Xencor, Inc BMP-7 variants with improved properties
CA2576113A1 (en) * 2004-08-10 2006-02-16 University College Cardiff Consultants Limited Methods and kit for the prognosis of breast cancer
EP1802326A2 (de) * 2004-09-09 2007-07-04 Stryker Corporation Verfahren zur behandlung von knochentumoren mit knochenmorphogenen proteinen
JP2008169116A (ja) * 2005-04-18 2008-07-24 Tokyo Medical & Dental Univ Ｂｍｐ−７を含む抗ｃ型肝炎ウイルス剤
US7851435B2 (en) 2005-05-27 2010-12-14 Bbs-Bioactive Bone Substitutes Oy Bone morphogenetic protein 3 and osteogenic devices and pharmaceutical products containing thereof
WO2006125867A1 (en) 2005-05-27 2006-11-30 Bbs-Bioactive Bone Substitutes Oy Bone morphogenetic protein 4 and osteogenic devices and pharmaceutical products containing thereof
ATE533781T1 (de) 2005-05-27 2011-12-15 Bbs Bioactive Bone Substitutes Oy Heparin-bindungsstelle enthaltendes knochenmorphogenetisches protein 6 und osteogene vorrichtungen und pharmazeutische produkte, die diese enthalten
ES2686093T3 (es) * 2005-07-19 2018-10-16 Stemgen S.P.A. Inhibición del potencial tumorigénico de células madre tumorales por BMP-4
GB0615129D0 (en) * 2006-07-29 2006-09-06 Univ Cardiff Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3627985B2 (ja) † 1991-03-11 2005-03-09 キュリス インコーポレイテッド タンパク質により誘導される形態形成
US5652118A (en) † 1991-03-11 1997-07-29 Creative Biomolecules, Inc. Nucleic acid encoding a novel morphogenic protein, OP-3
US6399569B1 (en) * 1991-03-11 2002-06-04 Curis, Inc. Morphogen treatments for limiting proliferation of epithelial cells
US6287816B1 (en) * 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
ES2201059T5 (es) † 1992-07-31 2007-11-01 Curis, Inc. Regeneracion y reparacion de nervios inducida por morfogenos.
JP4255986B2 (ja) * 1992-09-15 2009-04-22 ストライカー・コーポレーション 消化管潰瘍のモルフォゲン治療
US5863738A (en) † 1994-04-29 1999-01-26 Creative Biomolecules, Inc. Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides
JPH08225454A (ja) * 1995-02-23 1996-09-03 Chugai Pharmaceut Co Ltd マイクロスフェア製剤
FR2737501B1 (fr) * 1995-07-31 1997-10-24 Transgene Sa Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants
CA2232299A1 (en) † 1995-09-21 1997-03-27 The Trustees Of Columbia University In The City Of New York Uses of bone morphogenetic proteins
AU7473098A (en) * 1997-05-07 1998-11-27 Biogen, Inc. Novel therapies for cystic kidney disease

Also Published As

Publication number Publication date
DK1131087T3 (da) 2004-12-13
ES2226467T3 (es) 2005-03-16
EP1131087B2 (de) 2009-04-01
WO2000029012A8 (en) 2001-01-11
JP2010150278A (ja) 2010-07-08
ES2226467T5 (es) 2009-08-27
EP1131087A2 (de) 2001-09-12
PT1131087E (pt) 2004-12-31
EP1131087B1 (de) 2004-09-08
DE69920033T3 (de) 2009-10-08
JP4892131B2 (ja) 2012-03-07
WO2000029012A3 (en) 2000-11-16
EP1435243A3 (de) 2005-02-09
CA2349038C (en) 2011-08-02
AU1616700A (en) 2000-06-05
JP2002529513A (ja) 2002-09-10
DK1131087T4 (da) 2009-08-03
EP1435243A2 (de) 2004-07-07
WO2000029012A2 (en) 2000-05-25
DE69920033T2 (de) 2005-09-22
CA2349038A1 (en) 2000-05-25
DE69920033D1 (de) 2004-10-14

Similar Documents

Publication Publication Date Title
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
MX9603479A (es) Derivados de 4-amino de acido micofenolico con actividad inmunosupresora.
EP2082749A3 (de) Vorbeugung und Behandlung für Morbus Alzheimer
CA2391808A1 (en) Method for treatment of symptoms of central nervous system disorders
WO2001060347A3 (en) Method for treating ocular pain
DE69920033D1 (de) Verfahren zur verminderung von krebssymptomen
FR2808478B1 (fr) Moyen de securisation d'un substrat
WO1997003188A3 (de) Verwendung von mp52 oder mp121 zur behandlung und prävention von erkrankungen des nervensystems
WO2000013650A3 (en) Neuroprotection
CA2167004A1 (en) Agent for treating mental disorders associated with cerebrovascular disorders
EP1131107A4 (de) Antisense-modulation der expression von inhibitor-kappa-b-kinase-alpha
ES2180774T3 (es) La utilizacion de triacetato de glicerilo para el tratamiento de onicomicosis.
NO973589D0 (no) Medikament for behandlingen av besettende kompulsivproblemer, sövnapne, seksuelle funksjonsforstyrrelser, emesi og reisesyke
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
ATE172676T1 (de) Rasterbild und thermotransferfolie zu dessen herstellung
CA2153778A1 (en) Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
Font et al. Finding the words: Instruments for a therapy of liberation
AU1875395A (en) 4-amino derivatives of 5-substituted mycophenolic acid
MY124089A (en) Use of cetirizine for preventing the onset of asthma
PT1244498E (pt) Combinacao de trimebutina com um analgesico opiode
IT1319487B1 (it) Procedimento atto alla regolazione di un'operazione di avviamento inautoveicoli
CA2248753A1 (en) Use of olanzapine for treating excessive aggression
BR9714382A (pt) 17alfa-diidroequilina para uso como um antioxidante médico
ES2162062T3 (es) Estabilizacion de nitrilos.
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1131087

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1131087

Country of ref document: EP

EEIH Change in the person of patent owner